Document Detail


Induction of apoptosis in malignant and camptothecin-resistant human cells.
MedLine Citation:
PMID:  8993507     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Flow cytometry studies demonstrate that androgen-independent human prostate carcinoma DU-145 cells are arrested at the G1-phase of the cell cycle in the presence of suramin, but they die by apoptosis in the presence of 9-nitrocamptothecin (9NC). The addition of cytostatic concentrations of suramin increases the apoptotic action of 9NC on DU-145 cells, and induces apoptosis in 9NC-resistant DU-145/RC cells that were derived from the parental DU-145 cells by continuous exposure to progressively increased concentrations of 9NC. In addition, the topoisomerase II-directed drug etoposide exerts more extensive apoptotic action on DU-145/RC than DU-145 cells. Increased resistance of DU-145 cells to 9 NC and collaterally increased sensitivity to etoposide and suramin appear to correlate with alterations in the structure rather than synthesis of topoisomerases and possibly with specific cellular proteins that regulate apoptosis. The results suggest that etoposide and suramin may be successful alternative treatments for 9NC-resistant androgen-independent prostate cancer.
Authors:
D Chatterjee; J H Wyche; P Pantazis
Related Documents :
18980187 - Development of a stable dual cell-line gfp expression system to study estrogenic endocr...
20170107 - Influence of anthocyanins, derivative pigments and other catechol and pyrogallol-type p...
10715537 - A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen ef...
1384957 - Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer.
7666547 - Rapid induction of apoptosis by cell-to-cell transmission of human immunodeficiency vir...
6650117 - Volume changes during mitosis in pancreatic acinar cells of the rat.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of the New York Academy of Sciences     Volume:  803     ISSN:  0077-8923     ISO Abbreviation:  Ann. N. Y. Acad. Sci.     Publication Date:  1996 Dec 
Date Detail:
Created Date:  1997-01-29     Completed Date:  1997-01-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7506858     Medline TA:  Ann N Y Acad Sci     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  143-56     Citation Subset:  IM    
Affiliation:
Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Androgens / pharmacology
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects*
Camptothecin / analogs & derivatives*,  pharmacology
Cell Cycle / drug effects
Cell Cycle Proteins / metabolism
DNA Topoisomerases, Type I / metabolism
Drug Interactions
Drug Resistance
Enzyme Inhibitors / pharmacology
Etoposide / pharmacology
Humans
Male
Prostatic Neoplasms
Proto-Oncogene Proteins / metabolism
Proto-Oncogene Proteins c-bcl-2 / metabolism
Suramin / pharmacology
Tumor Cells, Cultured
bcl-2-Associated X Protein
Chemical
Reg. No./Substance:
0/Androgens; 0/Antineoplastic Agents; 0/Cell Cycle Proteins; 0/Enzyme Inhibitors; 0/Proto-Oncogene Proteins; 0/Proto-Oncogene Proteins c-bcl-2; 0/bcl-2-Associated X Protein; 104195-61-1/9-nitrocamptothecin; 145-63-1/Suramin; 33419-42-0/Etoposide; 7689-03-4/Camptothecin; EC 5.99.1.2/DNA Topoisomerases, Type I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effect of camptothecin on topoisomerase I catalysis.
Next Document:  Pharmacokinetics of camptothecins administered orally.